Research
GSK Stock: How the $9B Nuvalent Deal Reshapes Pipeline
The $9B Nuvalent deal lifts GSK net leverage to roughly 2.7x EBITDA but fills two oncology pipeline gaps. Risk-adjusted NPV at $10-12B supports the price.
NUVL
Nuvalent, Inc.
NASDAQ · USHealthcareBiotechnology
$123.96+0.00%
Price as of Jul 14, 2026
NUVL analysis
Nuvalent, Inc. stock analysis
Published Drillr research and company-specific analysis. Existing articles keep their current URLs and citation behavior.
Research
NUVL Stock: Why GSK's $9B Takeover Talks Matter
NUVL at $88.49 implies 25-35% probability the rumored $130-135 GSK deal closes. ROS1 and ALK CNS programs fit GSK pipeline gaps.